Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is a commercial-stage biotech firm that has shown strong financial performance due to its flagship drug Brukinsa, which makes up for the majority of its revenue. The company has also expanded its portfolio with the approval of two other drugs, Beqalzi and Tevimbra, with a focus on the Chinese market. Additionally, with over 50 drugs in clinical trials, BeOne has a promising drug pipeline that could continue to drive growth in the future, especially in the competitive market of oncology therapeutics.

Bears say

BeOne Medicines is a global commercial-stage biotech company specializing in the development and production of oncology therapeutics. While the company's main product, Brukinsa, has a strong global leadership position, its other approved drugs generate most of its revenue in China. The company also has a diverse pipeline of over 50 drugs in various stages of clinical trials targeting different forms of cancer. However, ONC faces potential challenges in implementing green manufacturing processes, ensuring clinical trial integrity and diversity, and socially responsible drug pricing, which may hinder long-term growth and limit upside potential.

BeiGene Ltd (ONC) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 12 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $387, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $387, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.